[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
October 4, 2006

Drug Safety Monitoring—Reply

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;296(13):1590. doi:10.1001/jama.296.13.1590-b

In Reply: Dr Ruck and colleagues propose the use of PCCs and their national database, TESS, as a tool for postmarketing drug surveillance. I have long thought that PCCs are an underused resource for the study of dose-related adverse drug reactions.1 After all, what better way to study such reactions than in an overdose setting? However, it is important to place this in proper perspective.

First Page Preview View Large
First page PDF preview
First page PDF preview